Expect Edwards Lifesciences' aggressive and increasingly hard-core heart valve patent battle with Medtronic to get worse in the coming weeks. An industry analyst predicts that a German court will issue an injunction preventing Medtronic from selling its CoreValve transcatheter aortic valve replacement in that country. And continued legal action is advancing in the U.S.
As Bloomberg reports, Germany's Der Spiegel has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall.
OrbusNeich Medical called the cops on Boston Scientific in Germany in a nasty escalation of their ongoing stent patent dispute.
Drugmakers, livid with German pricing gatekeepers for turning down so many new drugs, now face a strategy that is sure to ratchet up their anger to the boiling point.
A new survey analysis shows that patients in Germany and Italy are much less cynical about the pharmaceutical industry than U.S. patients are.
The well-armed German pricing gatekeepers have dismissed two more Big Pharma drugs. Pfizer's ($PFE) lung cancer treatment Xalkori and the Bristol-Myers Squibb ($BMY)/AstraZeneca ($AZN) diabetes drug Komboglyze both got an initial thumbs-down from the Institute for Quality and Efficiency in Health Care (IQWiG).
A flurry of letters promising to do better was not enough to keep the FDA from issuing a warning letter to a German maker of injectable drugs that outlines problems with its sterility procedures.
Last year, a German court told doctors they couldn't be punished for taking money or gifts from drugmakers--and neither can the companies, even if they're paying physicians specifically to prescribe their drugs. Now, state-backed insurers are calling for a major about-face. They want doctors who take kickbacks to go to prison.
Roche Diagnostics plans to pour more than $258 million into building a new diagnostics production complex in Germany, thanks to rising demand for immunoassays of all kinds.
AstraZeneca has had its own internal troubles in yielding new drugs from its R&D pipeline, but external factors such as drug pricing impact the industry.